On November 3, 2022 Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, reported that it will present initial data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 clinical trial at the 64th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, taking place December 10-13, 2022 in New Orleans, LA (Press release, Syros Pharmaceuticals, NOV 3, 2022, View Source [SID1234622918]). The SELECT-AML-1 trial is evaluating tamibarotene, Syros’ first-in-class selective retinoic acid receptor alpha (RARα) agonist, in combination with venetoclax and azacitidine in patients with newly diagnosed, unfit acute myeloid leukemia (AML) with RARA gene overexpression.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentation are as follows:

Presentation Title: Initial Results from SELECT-AML-1, a Phase 2 study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy
Session Title: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
Session Date & Time: Saturday, December 10, 2022, 5:30 – 7:30 pm CT (6:30 – 8:30 pm ET)
Location: Ernest N. Morial Convention Center, Hall D
Publication Number: 1444

The abstract is now available online on the ASH (Free ASH Whitepaper) Conference website at:
View Source